Abacus Planning Group Inc. cut its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) by 13.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 155,000 shares of the biotechnology company’s stock after selling 25,000 shares during the quarter. Pacific Biosciences of California makes up 0.8% of Abacus Planning Group […]
Operator
Thank you for standing by, and welcome to the Pacific Biosciences of California, Inc. fourth-quarter 2020 earnings conference call. [Operator instructions] I would now like to hand the conference over to Trevin Rard. Please go ahead.
Trevin Rard
Investor Relations
Thank you. Good afternoon, and welcome to the Pacific Biosciences fourth-quarter 2020 earnings conference call. We hope that you re keeping well during this time. Earlier today, we issued a press release outlining the financial results we ll be discussing on today s call, a copy of which is available on the Investors section of our website at www.pacb.com or, alternatively, as furnished on Form 8-K available on the Securities and Exchange Commission website at www.sec.gov.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pacific Biosciences of California, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial .
Pacific Biosciences of California, Inc.February 10, 2021 GMT
MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Reported revenue is consistent with the Company’s press release issued on January 11, 2021.
Q4 2020 Financial Highlights
Revenue for the fourth quarter of 2020 was $27.1 million, representing a 42% increase sequentially compared with $19.1 million for the third quarter of 2020 and a 3% decrease compared with $27.9 million for the fourth quarter of 2019. The Company placed 35 Sequel II/IIe systems during the fourth quarter, bringing the total installed base of Sequel II/IIe systems up to 203 as of December 31, 2020, compared with 1
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pacific Biosciences Grants Equity Incentive Awards to New Employees
Pacific Biosciences of California, Inc.January 12, 2021 GMT
MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options covering an aggregate of 750,000 shares of Pacific Biosciences common stock and restricted stock units (“RSUs”) covering 335,000 shares of Pacific Biosciences common stock to the Company’s recently hired Chief Operating Officer, Mark Van Oene, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “Inducement Plan”) effective on January 8, 2021.
Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue
Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue
MENLO PARK, Calif., Jan. 11, 2021 Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020. The Company’s full financial results for the fourth quarter and the fiscal year ended December 31, 2020 are not yet available.
Financial and Operational Highlights
Preliminary fourth quarter revenue is expected to be approximately $27 million, representing an estimated increase of approximately 41% sequentially compared with $19.1 million for the third quarter of 2020.